Your browser doesn't support javascript.
loading
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer.
Medford, Arielle J; Dubash, Taronish D; Juric, Dejan; Spring, Laura; Niemierko, Andrzej; Vidula, Neelima; Peppercorn, Jeffrey; Isakoff, Steven; Reeves, Brittany A; LiCausi, Joseph A; Wesley, Benjamin; Malvarosa, Giuliana; Yuen, Megan; Wittner, Ben S; Lawrence, Michael S; Iafrate, A John; Ellisen, Leif; Moy, Beverly; Toner, Mehmet; Maheswaran, Shyamala; Haber, Daniel A; Bardia, Aditya.
Afiliação
  • Medford AJ; 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129 USA.
  • Dubash TD; 2Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114 USA.
  • Juric D; 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129 USA.
  • Spring L; 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129 USA.
  • Niemierko A; 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129 USA.
  • Vidula N; 2Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114 USA.
  • Peppercorn J; 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129 USA.
  • Isakoff S; 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129 USA.
  • Reeves BA; 2Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114 USA.
  • LiCausi JA; 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129 USA.
  • Wesley B; 2Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114 USA.
  • Malvarosa G; 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129 USA.
  • Yuen M; 2Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114 USA.
  • Wittner BS; 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129 USA.
  • Lawrence MS; 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129 USA.
  • Iafrate AJ; 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129 USA.
  • Ellisen L; 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129 USA.
  • Moy B; 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129 USA.
  • Toner M; 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129 USA.
  • Maheswaran S; 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129 USA.
  • Haber DA; 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129 USA.
  • Bardia A; 3Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114 USA.
NPJ Precis Oncol ; 3: 18, 2019.
Article em En | MEDLINE | ID: mdl-31341951
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article